{"organizations": [], "uuid": "c536f9feb11d0f0834229207ca29f2189189403e", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180212.html", "section_title": "Archive News &amp; Video for Monday, 12 Feb 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-pacira-pharma-says-fda-posts-brief/brief-pacira-pharma-says-fda-posts-briefing-documents-for-advisory-meeting-reviewing-snda-for-exparel-idUSFWN1Q21D6", "country": "US", "domain_rank": 408, "title": "BRIEF-Pacira Pharma says FDA Posts Briefing Documents For Advisory Meeting Reviewing SNDA For Exparel", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.016, "site_type": "news", "published": "2018-02-13T04:04:00.000+02:00", "replies_count": 0, "uuid": "c536f9feb11d0f0834229207ca29f2189189403e"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-pacira-pharma-says-fda-posts-brief/brief-pacira-pharma-says-fda-posts-briefing-documents-for-advisory-meeting-reviewing-snda-for-exparel-idUSFWN1Q21D6", "ord_in_thread": 0, "title": "BRIEF-Pacira Pharma says FDA Posts Briefing Documents For Advisory Meeting Reviewing SNDA For Exparel", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "fda", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}, {"name": "pacira pharmaceuticals inc", "sentiment": "negative"}, {"name": "brief-pacira pharma", "sentiment": "negative"}, {"name": "exparel", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Feb 12 (Reuters) - Pacira Pharmaceuticals Inc:\n* PACIRA PHARMACEUTICALS INC - FDA POSTS BRIEFING DOCUMENTS FOR ADVISORY MEETING REVIEWING SNDA FOR EXPAREL AS A NERVE BLOCK FOR REGIONAL ANALGESIA\n* PACIRA PHARMACEUTICALS INC - ‍PRESCRIPTION DRUG USER FEE ACT DATE FOR COMPLETION OF FDA‘S REVIEW OF COMPANY‘S SNDA FOR EXPAREL IS APRIL 6, 2018​\n* PACIRA PHARMACEUTICALS INC - ADVISORY COMMITTEE MEETING IS SCHEDULED FOR FEBRUARY 14-15, 2018 Source text for Eikon: Further company coverage:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-02-13T04:04:00.000+02:00", "crawled": "2018-02-13T15:29:12.014+02:00", "highlightTitle": ""}